<?xml version="1.0" encoding="UTF-8"?>
<ref id="B88-pharmaceuticals-12-00060">
 <label>88.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Baz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Goyette</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Griffin</surname>
    <given-names>B.D.</given-names>
   </name>
   <name>
    <surname>Kobinger</surname>
    <given-names>G.P.</given-names>
   </name>
   <name>
    <surname>Boivin</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin</article-title>
  <source>Antivir. Ther.</source>
  <year>2017</year>
  <volume>22</volume>
  <fpage>613</fpage>
  <lpage>618</lpage>
  <pub-id pub-id-type="doi">10.3851/IMP3180</pub-id>
  <pub-id pub-id-type="pmid">28694390</pub-id>
 </element-citation>
</ref>
